A Phase 2a study of Xiflam in Long COVID patients
Completed Phase 2 NCT06437223
Study Description
A study to evaluate the safety and effectiveness of Xiflam in treating Long COVID symptoms
Study Details
- Registry ID:
- NCT06437223
- Conditions:
- Long COVID
- Phase:
- Phase 2
- Target Enrollment:
- 16 participants
- Start Date:
- Age Range:
- 21–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Massachusetts Eye Research and Surgery Institution (MERSI)
Waltham, Massachusetts, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.